Mitsubishi Chemical–Bain Capital: investment, 202502– carve-out acquisition JPY510b ($3.3b) of Mitsubishi Tanabe Pharma Corp by Bain Capital |
2025-02-07 |
Bureau Veritas–SGS: investment, 202501– confirmed merger discussion |
2025-01-15 |
Owlstone–Horizons Ventures: investment, 202501 financing round Series E first closing totalling $27m incl existing + co-investor Horizon Ventures |
2025-01-15 |
Owlstone–SEVERAL: investment, 202501 financing round Series E first closing $27m led by Ventura Capital |
2025-01-15 |
Owlstone–Ventura Capital: investment, 202501 financing round Series E first closing totalling $27m incl existing + lead investor Ventura Capital |
2025-01-15 |
Bioptimus–Hitachi: investment, 202501 financing round totalling $41m incl co-investor Hitachi Ventures |
2025-01-14 |
Bioptimus–SEVERAL: investment, 202501 financing round $41m led by Cathay Innovation |
2025-01-14 |
Umoja Biopharma–SEVERAL: investment, 202501 financing round Series C $100m co-led by Double Point Ventures + DCVC Bio |
2025-01-14 |
Daiichi Sankyo–Glycotope: antibody-drug conjugates, 202501 acquisition all IPRs $132.5m for use of gatipotuzumab in ADC DS-3939 |
2025-01-13 |
Normunity–SEVERAL: investment, 202501 financing round Series B $75m co-led by Samsara BioCapital + Enavate Sciences |
2025-01-13 |
Windward Bio–Kelun Pharmaceutical: TSLP antibody, 202501– license ww excl China + smaller Asian markets to WIN378 from Kelun-Biotech + Harbour Biomed |
2025-01-10 |
Windward Bio–Nan Fung: investment, 202501 financing round Series A totalling $200m incl co-investor Pivotal bioVenture Partners |
2025-01-10 |
Windward Bio–Qiming: investment, 202501 financing round Series A totalling $200m incl co-investor Qiming Venture Partners |
2025-01-10 |
Windward Bio–Quan Capital: investment, 202501 financing round Series A totalling $200m incl co-investor Quan Capital |
2025-01-10 |
Windward Bio–SEVERAL: investment, 202501 financing round Series A $200m led by OrbiMed + Novo Holdings + Blue Owl Healthcare Opportunities |
2025-01-10 |
Roche–Innovent Biologics: antibody-drug conjugate, 202501– collab + excl ww license to IBI3009 with $80m upfront + $1b milestones plus royalties |
2025-01-02 |
Astellas–Sangamo: drug delivery for gene therapies, 202412– license excl ww $20m upfront + up to $1.3b use STAC-BBB capsid |
2024-12-19 |
Innovent Biologics–Lilly: pirtobrutinib, 202412– distribution excl commercialisation of Jaypirca in mainland China by Innovent Biologics |
2024-12-16 |
Syncell–SEVERAL: investment, 202412 financing round Series A $15m led by Taiwania Capital Bio Fund bringing total raised to $30m |
2024-12-11 |
Syncell–Taiwania Capital: investment, 202412 financing round Series A totalling $15m incl lead investor Taiwania Capital Bio Fund |
2024-12-11 |
Biotheus–BioNTech: investment, 202411– acquisition 100% for $800m upfront mostly in cash + few ADSs plus $150m milestones |
2024-11-13 |
Centogene–Charme Capital Partners: investment, 202411– acquisition €8.7m of sole operating subsidiary Centogene GmbH by affiliate of Charme Capital |
2024-11-13 |
Alentis Therapeutics–Morningside: investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor Morningside VI |
2024-11-12 |
Alentis Therapeutics–SEVERAL: investment, 202411 financing round Series D $181.4m led by OrbiMed with co-leads Novo Holdings + Jeito Capital |
2024-11-12 |
Nuclera–E Ink: investment, 202410 financing round Series C totalling $75m incl existing + co-investor E Ink Holdings |
2024-10-16 |
Nuclera–GK Goh: investment, 202410 financing round Series C totalling $75m incl existing + co-investor GK Goh |
2024-10-16 |
Nuclera–PERSON: investment, 202410 financing round Series C totalling $75m incl co-investor Michael D McCreary |
2024-10-16 |
Nuclera–SEVERAL: investment, 202410 financing round Series C $75m led by Elevage Medical Technologies (Patient Square Capital) |
2024-10-16 |
Innovent Biologics–Aosaikang Pharmaceuticals: limertinib, 202410– distribution excl commercialisation of limertinib in mainland China by Innovent |
2024-10-08 |
Yumab–Molcure: AI-based drug discovery, 202410– collab expansion to incl zero-shot AI Ab discovery technology to discover Abs for undrugged targets |
2024-10-08 |
Kurma–SEVERAL: investment, 202410 first closing of Kurma Biofund IV with target for final closing of €250m |
2024-10-03 |
Roche–Regor: CDK inhibitors, 202409– acquisition $850m cash upfront + milestones of portfolio of CDK inhibitors by Genentech from Regor |
2024-09-30 |
Resonac–Altaris: investment, 202409– acquisition 100% of Minaris Regenerative Medicine Subsidiaries of Resonac by Altaris LLC |
2024-09-26 |
Shan Foods–Symrise: foods, 202409 strategic collab existent Pakistan + UAE + KSA incl joint production plant in Pakistan |
2024-09-20 |
Cell Signaling Technology–e-Blot Life Science: imaging system, 202409– distribution of Touch Imager system by Bioké in 12 European countries |
2024-09-16 |
Abolis Biotechnologies–Clay Capital: investment, 202409 financing round totalling €35m incl investor Clay Capital |
2024-09-12 |
Abolis Biotechnologies–SEVERAL: investment, 202409 financing round €35m with BOLD L’Oréal VC Fund + Evonik Venture Capital et al |
2024-09-12 |
Organon–Bao Pharmaceutical: long-acting FSH, 202409– license + supply agreem for SJ02 in Mainland China $12m upfront + milestones |
2024-09-12 |
PhoreMost–SEVERAL: investment, 202409 financing round Series B extension $12m bringing total round to $50m led by Parkwalk Advisors |
2024-09-10 |
Candid Therapeutics–SEVERAL: investment, 202409 launches with $370m investment raised via multi-step financing |
2024-09-09 |
eGenesis–SEVERAL: investment, 202409 financing round Series D $191m from existing + new investors led by Lux Capital |
2024-09-04 |
Vignette Bio–EpimAb Biotherapeutics: bispecific antibody, 202409– license ww outside China $60m upfront cash+equity + $575m milestones + royalties |
2024-09-04 |
Vignette Bio–EpimAb Biotherapeutics: investment, 202409 equity investment as part of $60m upfront payment in cash + equity in license deal |
2024-09-04 |
Vignette Bio–Foresite Capital: investment, <202409 seed financing round incl lead investor Foresite Capital |
2024-09-04 |
Vignette Bio–Mirae Asset: investment, <202409 seed financing round incl co-investor Mirae Asset Capital Life Science |
2024-09-04 |
Vignette Bio–Qiming: investment, <202409 seed financing round incl co-investor Qiming Venture Parnters USA |
2024-09-04 |
Vignette Bio–Samsara BioCapital: investment, <202409 seed financing round incl co-investor Samsara BioCapital |
2024-09-04 |
Vignette Bio–SEVERAL: investment, <202409 seed financing round led by Foresite Capital |
2024-09-04 |
Vandria–Hevolution Foundation: investment, 202408 financing round Series A 2nd closing totalling CHF10.3m incl new investor Hevolution Foundation |
2024-08-21 |
Vandria–SEVERAL: investment, 202408 financing round Series A 2nd closing CHF10.3m bringing total Series A to CHF28.3m |
2024-08-21 |
PL BioScience–LePure Biotech: investment, 202408 financing round Series A totalling €7.8m incl new investor LePure Biotech |
2024-08-08 |
PL BioScience–SEVERAL: investment, 202408 financing round Series A €7.8m with new + existing investors |
2024-08-08 |
NEC–Asahi Glass: contract manufacturing, 202408– collab developm production techn + supply cancer vaccine NECVAX-NEO1 by AGC Biologics + NEC Bio Tx |
2024-08-07 |
Leon-Nanodrugs–SEVERAL: investment, 202408 financing round Series D led by new investor LBBW Venture Capital |
2024-08-06 |
Kirin–Biomatter Designs: enzyme design, 202408 collab existent development of enzymes for production of Human Milk Oligsaccharides (HMOs) |
2024-08-05 |
AIRNA–SEVERAL: investment, 202407 financing round Series A extension $60m led by Forbion brings total Series A to $90m |
2024-07-31 |
iotaSciences–SEVERAL: investment, 202407 equity financing round from existing + new investors for business expansion |
2024-07-31 |
Ono Pharmaceutical–Systasy Bioscience: drug target discovery, 202407– collab research fees + milestones to identify + validate targets in neurology |
2024-07-31 |
Synthetica Pioneering–Boehringer: investment, 202407 financing round Series A incl co-lead investor Boehringer Ingelheim Venture Fund |
2024-07-30 |
Synthetica Pioneering–SEVERAL: investment, 202407 financing round Series A led by Boehringer Ingelheim Venture Fund + Temasek |
2024-07-30 |
Revir Therapeutics–5Y Capital: investment, 202407 financing round Series A totalling $30m incl existing + co-investor 5Y Capital |
2024-07-26 |
Revir Therapeutics–CDH Investments: investment, 202407 financing round Series A totalling $30m incl existing + co-investor CDH Investments |
2024-07-26 |
Revir Therapeutics–CMT Research Foundation: investment, 202407 financing round Series A totalling $30m incl new + co-investor CMTRF |
2024-07-26 |
Revir Therapeutics–Lapam Capital: investment, 202407 financing round Series A totalling $30m incl lead investor Lapam Capital |
2024-07-26 |
Revir Therapeutics–SEVERAL: investment, 202407 financing round Series A $30m led by Lapam Capital bringing total raise to $54m |
2024-07-26 |
Revir Therapeutics–XtalPi: AI-based drug discovery, 202407 collab existent |
2024-07-26 |
Revir Therapeutics–XtalPi: investment, 202407 financing round Series A totalling $30m incl new + co-investor XtalPi |
2024-07-26 |
Revir Therapeutics–Yael Capital: investment, 202407 financing round Series A totalling $30m incl existing + co-investor Yael Capital |
2024-07-26 |
BioNTech–Triastek: 3D drug printing, 202407– collab developm + license $10m upfront + $1.2b milestones plus royalties 3D printed oral RNA drugs |
2024-07-23 |
CytoReason–Nvidia: investment, 202407 financing round totalling $80m incl investor Nvidia |
2024-07-17 |
CytoReason–OurCrowd: investment, 202407 financing round totalling $80m incl investor OurCrowd |
2024-07-17 |
CytoReason–Pfizer: investment, 202407 financing round totalling $80m incl investor Pfizer |
2024-07-17 |
CytoReason–SEVERAL: investment, 202407 financing round $80m from OurCrowd + Nvidia + Pfizer + Thermo Fisher |
2024-07-17 |
CytoReason–Thermo Fisher: investment, 202407 financing round totalling $80m incl investor Thermo Fisher Scientific |
2024-07-17 |
Draupnir Bio–Mitsubishi Chemical: Investment, 202407 seed financing round totalling €12m incl new investor MP Healthcare |
2024-07-17 |
Draupnir Bio–SEVERAL: Investment, 202407 seed financing round €12m with MP Healthcare + EIFO + Gilde HP + Inkef Capital + Novo Holdings |
2024-07-17 |
SK Group–Full-Life Technologies: radionuclide-drug conjugate, 202407– license ww excl up to $571.5m to FL-091 anti-NTSR1 to SK Biopharmaceuticals |
2024-07-17 |
Catalym–Brandon Capital: investment, 202407 financing round Series D totalling $150m incl existing + co-investor Brandon Capital |
2024-07-16 |
Catalym–Canaan Partners: investment, 202407 financing round Series D totalling $150m incl new + co-lead investor Canaan Partners |
2024-07-16 |
Catalym–SEVERAL: investment, 202407 financing round Series D $150m led by Canaan Partners + Bioqube Ventures |
2024-07-16 |
Huma Therapeutics–Hitachi: investment, 202407 financing round Series D totalling >$80m incl investor HV Fund |
2024-07-16 |
Huma Therapeutics–SEVERAL: investment, 202407 financing round Series D >$80m (alongside investments from industry partners since Series C) |
2024-07-16 |
Scorpion Therapeutics–SEVERAL: investment, 202407 financing round Series C $150m led by Frazier Life Sciences + Lightspeed Venture Partners |
2024-07-16 |
Element Biosciences–Fidelity: investment, 202407 financing round Series D totalling >$277m incl existing + co-investor Fidelity |
2024-07-11 |
Element Biosciences–Foresite Capital: investment, 202407 financing round Series D totalling >$277m incl existing + co-investor Foresite Capital |
2024-07-11 |
Element Biosciences–Rockefeller: investment, 202407 financing round Series D totalling >$277m incl existing + co-investor Venrock |
2024-07-11 |
Element Biosciences–Samsung: investment, 202407 financing round Series D totalling >$277m incl co-investor Samsung Electronics |
2024-07-11 |
Element Biosciences–SEVERAL: investment, 202407 financing round Series D over $277m led by Wellington Management |
2024-07-11 |
Element Biosciences–T Rowe Price: investment, 202407 financing round Series D totalling >$277m incl existing + co-investor T Rowe Price Associates |
2024-07-11 |
Ipsen–Foreseen Biotechnology: antibody-drug conjugate, 202407– license ww excl to FS001 up to $1.03b |
2024-07-11 |
Endoron Medical–SEVERAL: investment, 202407 financing round Series A $10m led by Sofinnova Partners |
2024-07-09 |
Myricx Pharma–Brandon Capital: investment, 202407 financing round Seires A totalling £90m incl existing + co-investor Brandon Capital |
2024-07-08 |
Myricx Pharma–SEVERAL: investment, 202407 financing round Seires A £90m led by Novo Holidngs + Abingworth |
2024-07-08 |
Nucleai MD–Proscia: AI-based diagnostics, 202406– collab integration of Nucleai predictive biomarker solutions into Concentriq s/w platform |
2024-06-25 |
Iambic Therapeutics–SEVERAL: investment, 202406 financing round Series B extension $50m led by Mubadala Capital + Exor Ventures |
2024-06-18 |
Adcytherix–Pontifax: investment, 202406 seed financing round totalling €30m incl lead investor Pontifax Venture Capital |
2024-06-11 |
ITM–Qatar (govt): investment, 202406 financing round totalling €188m incl exisitng + co-investor Qatar Investment Authority |
2024-06-06 |
ITM–SEVERAL: investment, 202406 financing round €188m led by Temasek + including other exisitng investors |
2024-06-06 |
ITM–Temasek: investment, 202406 financing round totalling €188m incl exisitng + lead investor Temasek |
2024-06-06 |
Brandon Capital–Hesta (AU): investment, 202406 first closing of Brandon Capital Fund VI totalling AUD270m incl existing investor Hesta |
2024-06-04 |